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The use of drugs in fixed-dose combination (FDC) is now recommended by the World Health Organization 
(WHO) due to the emergence of multidrug-resistant strains of Mycobacterium tuberculosis. FDC uses 
different drugs against tuberculosis (TB) in a single tablet for phase-intensive therapeutic intervention. 
This therapy aims to optimize treatment, to prevent inappropriate use of drugs, and to prevent the 
emergence of new resistant strains. This study aims to evaluate the susceptibility of clinical isolates 
of M. tuberculosis against rifampicin, isoniazid, ethambutol, and pyrazinamide. The antimicrobials 
were tested separately and in associations according to FDC. This was used for broth microdilution 
method, which was compared to the proportions method previously considered as the gold standard. In 
antimicrobials testing alone, several strains were resistant to one, two, or three drugs. However, when 
applied to association of drugs in FDC, there was no antimicrobial resistance. The results strengthen the 
FDC’s concept, which aims to unite the four anti-TB drugs to combat bacterial resistance.
Uniterms: Mycobacterium tuberculosis/treatment/drug combination. Mycobacterium tuberculosis/drug 
resistance. Mycobacterium tuberculosis/susceptibility/fixed dose combination.
INTRODUCTION
Defined as an infectious disease of the lungs, 
tuberculosis (TB) is  caused by Mycobacterium 
tuberculosis. The World Health Organization (WHO) 
estimates that, in 2014, there was an incidence of 9.6 
millions of new cases of tuberculosis worldwide. During 
this period, around 1.1 million people died of TB (WHO, 
2015).
There is an increase in the incidence of multi-
resistant strains of M. tuberculosis, which may be caused, 
among other factors, by the lack of patient adherence to 
TB treatment, as this is extensive and may cause relevant 
side effects (Mitchison, Davies, 2012). The clinical 
impact of this resistance is immense, being characterized 
by an increase in treatment costs as well as an increase 
in morbidity and mortality (Lee et al., 2009). The 
inappropriate use of conventional antimicrobials for the 
treatment of microbial infections has contributed to the 
increase of rates of resistance (Mitchison, Davies, 2012).
TB control measures, such as vaccination with BCG 
(Bacillus Calmette-Guérin) and chemoprophylaxis, appear 
to be unsatisfactory. The role of BCG vaccination is just 
to provide a degree of protection against severe forms 
of TB. Thus, the key to the control of the infection is the 
rapid diagnosis and cure of patients infected (Campbell, 
Bah-Sow, 2006).
TB can usually be treated with a standard course of 
four drugs, rifampicin (R), isoniazid (H), pyrazinamide 
(Z), and ethambutol (E), also known as first-line 
antituberculosis drugs (Mitnikc, McGee, Peloquin, 2009). 
Currently, several authors have reported synthetic or 
natural substances that are able to inhibit the growth of 
M. tuberculosis, but more studies are needed so that they 
become a viable alternative in the treatment of patients 
(Agertt et al., 2012; Boligon et al., 2012; Gising et al., 
Nielsen et al., 2012; Pucci et al., 2010; Vilchèze et al., 
2011). Further clinical trials, probably not complete 
studies on new drugs against TB in the next 10 years, 
are urgently needed for the rational and adequate use of 
rifampicin and isoniazid once its use as monotherapy 
induces primary resistance (Hall, Leff, Gumbo, 2009). 
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To prevent multidrug resistance, WHO recommends 
the use of a fixed-dose combination (FDC) of drugs for 
the treatment of TB (Blomberg et al., 2001). FDCs are 
formulations containing two or more antituberculosis 
drugs combined in a single tablet. At the stage of 
intensive care, the tablet contains 150 mg of rifampicin, 
75 mg of isoniazid, 400 mg of ethambutol, and 275 mg 
of pyrazinamide. The maintenance phase consists of one 
tablet composed of 150 mg of rifampicin and 75 mg of 
isoniazid (Blomberg, Fourie, 2003). 
While preventing the monotherapy and facilitating 
the ingestion of appropriate doses of antituberculosis 
drugs, it is expected that FDC helps prevent the emergence 
of antimicrobial resistance. Other advantages of the 
implementation of FDC are: simplification of treatment, 
reduction of medication prescribing errors, improved patient 
adherence to treatment, reduced treatment supervision, 
management simplification in the supply of drugs, 
calculated drug needs, as well as ensuring the availability 
of high-quality drugs and delivery of the correct dose of all 
drugs to the patient. In addition, FDC does not produce more 
adverse effects than the equivalent combinations of drugs 
formulated separately (Blomberg, Fourie, 2003). 
Due to the high incidence of TB and the emergence 
of resistant strains, monitoring and evaluation of the 
susceptibility profile of the antituberculosis drugs in 
clinical isolates are necessary measures to control 
tuberculosis. Moreover, a better understanding of bacterial 
behavior in relation to drug therapies currently applied 
in patients with active TB can assist in the therapeutic 
effectiveness and success of the treatment.
MATERIALS AND METHODS
The bacilli isolated from patients with tuberculosis 
were from the Clinical Laboratory of the University 
Hospital of Santa Maria - LAC-HUSM, which receives 
patients from throughout Central Southern Brazil in the 
period from January to December 2010. We analyzed 
the cultures of the samples collected from patients with 
suspected tuberculosis who obtained positive smear 
and culture, as directed by the Manual for Tuberculosis 
Bacteriology (BRASIL, 2005).
A small portion of the positive cultures was removed 
for re-plating and isolation in Lowenstein-Jensen (LJ). 
Tests were performed to differentiate between non-
tuberculous mycobacteria and bacteria probably belonging 
to the M. tuberculosis complex directed by the Manual for 
Tuberculosis Bacteriology (BRASIL, 2005).
After the samples were classified by phenotypic 
and biochemical tests as belonging to the M. tuberculosis, 
identification was confirmed using molecular techniques. 
The samples were examined for the presence of IS6110 
insertion by the polymerase chain reaction as described 
by Eisenach et al. (1990). 
The 42 crops confirmed by molecular technique as 
M. tuberculosis and standard strain H37Rv were evaluated 
for susceptibility to antimicrobial agents (R, H, E, Z), 
according to the proportions method (PM) (Canetti et 
al., 1969) and the broth microdilution method (BMM). 
Subsequently, the microorganisms were tested against 
antimicrobial associated as a fixed-dose combination 
through the BMM.
Determination of the Minimum Inhibitory 
Concentration (MIC) of antimicrobials alone and in 
combination (R, H, Z, and E (Sigma®)) was performed by 
the adapted BMM (NCCLS, 2003; Franzblau et al., 1998; 
Syre, Ovrea, Grewal, 2010). Rifampicin was dissolved 
in methanol and other drugs in sterile ultrapure water as 
specified by the manufacturer. The primary dilutions were 
adjusted to the desired concentration in 7H9 Middlebrook 
medium base pH (6.6) supplemented with 10% OADC 
(oleic acid-albumin-dextrose-catalase) (Difco Laboratories, 
Detriot, Mich) and 0.2% glycerol (MD7H9). R and H were 
tested at concentrations of 0.25, 0.5, 1.0, 2.0, 4.0, and 8.0 
mg/mL, the Z concentrations of 25, 50, 100, 200, 400 to 800 
mg/mL, and E at concentrations of 4.0, 8.0, 16, 32, 64 to 
128 mg/mL. These four drugs were tested in combination, 
at the same concentrations in BMM; therefore, the 
concentration of each drug used in the tests was equal to the 
isolated drugs. The bacterial suspensions were prepared in 
MD7H9 medium and incubated at 35 °C for 7 days in tubes 
containing glass beads of 2-mm diameter, for subsequent 
homogenization and dissolution on a vortex mixer. The 
bacterial suspension was adjusted to the MacFarland scale 
1 and was then diluted 1/25 in MD7H9 at the time of use.
The BMM was performed on 96-well cell culture 
dishes. Colony growth was observed by the appearance 
of white dots without the use of dyes. Strains were 
considered resistant if they possessed the superior growth 
at concentrations of 1 µg/mL for R and H, 16 µg/mL for 
E, 100 µg/mL for Z, and 1/1/16/100 µg/mL (R/H/E/Z) for 
the association.
The study protocol was approved by the Ethics 
Committee of the Federal University of Santa Maria 
(UFSM) by CAAE number (Certificate presentation for 
Ethical Consideration) 0104.0.243.000-11.
RESULTS
Eighteen clinical isolates were resistant using the 
proportions method, including 10 resistant to one drug, 5 
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resistant to two drugs, and 3 resistant to the three drugs. 
Figure 1 shows these proportions. Through microdilution 
method, 28 resistant isolates were found, including 16 
resistant to one drug, 4 resistant to two drugs, and 8 
resistant to the three drugs, which can be seen in Figure 2. 
The correlation between the methods is illustrated in 
Figure 3.
The isolates, when tested against four associated 
drugs, were considered all susceptible. Thirty-eight 
isolates showed an MIC ≤ 0.25/0.25/4/25 µg/mL (R/H/
E/Z), three showed MIC equal to 0.5/0.5/8/50 µg/mL, 
and one isolate showed MIC equal to 1/1/16/100 µg/mL 
(R/H/E/Z). Among these four, three isolates were resistant 
to isoniazid, ethambutol, and pyrazinamide when tested 
alone at MMC.
DISCUSSION 
The identification of clinical isolates belonging to 
the M. tuberculosis complex was satisfactory, because 
100% of the isolates characterized by the classical method 
(LJ with PNB) were also positive for the IS6110 insertion. 
The M. tuberculosis complex is composed of M. bovis, 
M. microti, and M. africanum, the latter two being found 
at low frequency in Brazil (BRASIL, 2005). M. bovis 
requires more stringent conditions to grow in culture, 
such as the addition of sodium pyruvate to the LJ medium, 
therefore, the analyzed isolates can be M. tuberculosis, 
because the medium used for growth of the samples was 
LJ, not enriched for M. bovis.
Susceptibility tests carried out in liquid media 
are more sensitive than those using solid media, as the 
techniques of solid media use only drug concentration, 
whereas the techniques of a liquid medium make it 
possible to use various concentrations, increasing the 
evaluation possibilities.
Six clinical isolates resistant to rifampicin were 
detected using the proportion method, however, they 
showed less MICs of 0.25 mg/mL by microdilution broth 
method (Figure 3A). This may be due to one-off losses 
of rifampicin activity when LJ medium was coagulated. 
Seven strains were considered susceptible to 
isoniazid using broth microdilution method, but were 
resistant in the proportion method (Figure 3B). This is 
based on the fact that these strains were susceptible with 
an MIC ≤0.25 µg/mL, and the concentration used in the LJ 
medium was 0.2 µg/mL in the proportion method; the MIC 
values should be between 0.2 and 0.25 µg/mL in order for 
the isolates to be considered susceptible.
Four strains were considered susceptible to 
ethambutol in broth microdilution method, however, such 
resistance is present when measured using the proportions 
method (Figure 3C). This was probably due to the fact 
that the strains with MIC present a sensitivity ≤ 4 µg/
mL, the concentration ratio of the method used in the LJ 
medium was 2 µg/mL, and the MIC values were supposed 
to be between 2 and 4 µg/mL. Thus, these isolates are 
considered susceptible.
Strains resistant to pyrazinamide were detected 
using broth microdilution method, which did not 
correspond with the proportion method (Figure 3D). 
This may have occurred because pyrazinamide has its 
great efficacy against microorganisms while at acidic pH, 
FIGURE 1 - Percentage of resistant strains by the proportions 
method. Rifampicin (R), isoniazid (H), pyrazinamide (Z), 
ethambutol (E).
FIGURE 2 - Percentage of resistant strains by broth microdilution 
method. Isoniazid (H), pyrazinamide (Z), ethambutol (E).
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which was not observed in broth microdilution method. 
This occurred because broth microdilution method was 
used as a reference that proves that a cutoff value of 100 
μg/mL of pyrazinamide revealed no changes in the results 
due to the pH (Syre, Ovrea, Grewal, 2010). Zhang, Zhang, 
Sun, (2003) proved that it is difficult for M. tuberculosis 
to maintain a neutral internal pH due to environmental 
conditions that cause an acidic pH. The accumulation of 
weak acid could lead to the disruption of a proton-motive 
force, which is necessary for the transport of many nutrient 
substances to bacterial cells. However, weak acids that may 
be present in the inflammation process have an influence 
on the in vitro activity of pyrazinamide. The exposure for a 
short time of less than 3 to 5 days hardly shows any activity 
of pyrazinamide. This time, it is necessary to convert the 
prodrug pyrazinamide to pyrazinoic acid, which will act 
against the microorganism (Wade, Zhang, 2006). The in 
vitro testing for pyrazinamide still needs further studies to 
establish a better specificity of the methods, including the 
one conducted in this study which showed a value of false-
positive high when compared with the reference method.
Although various strains resistant to one, two, or 
three drugs were detected when tested separately by BMM, 
no strain was considered resistant when tested against four 
FIGURE 3 - Correlation between the MICs (mg/mL) found in the broth microdilution method and the proportions method classified 
to rifampicin (A), isoniazid (B), ethambutol (C), and pyrazinamide (D). ● isolates that showed agreement between the methods. 
■ isolates exhibiting disagreement among methods. The vertical lines separating isolates from the resistant and susceptible proportion 
method. The horizontal lines separating the susceptible and resistant isolates in the broth microdilution method.
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drugs associated by that method. This fact is in line with 
the concept of FDC, which united the four anti-TB drugs to 
combat the resistance of the bacilli. As studies have shown 
the bioequivalence between drugs of FDC (Agrawal et al., 
2002), we showed in vitro that the use of FDC will combat 
the strains of M. tuberculosis resistant to first-line drugs 
used against TB.
According to Blomberg and Fourie (2003), to 
prevent monotherapy and facilitate the ingestion of 
appropriate doses of anti-TB drugs, it is expected that 
FDC will help prevent the emergence of drug resistance. 
With our study, we can say that FCD can fight resistant 
strains by not allowing more mutant bacilli emerge in the 
monotherapy.
The BMM proved to be a fast, easy to perform and 
well correlated with the PM, considered the gold standard 
for mycobacteria susceptibility methods, which can 
be used for epidemiological studies. A study involving 
a larger number of clinical isolates, and monitoring 
the treatment of infected patients would be of great 
epidemiological importance. This study then becomes 
a basis for further studies on the effectiveness in the 
treatment of tuberculosis.
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